Maureen McKeague
Overview
Explore the profile of Maureen McKeague including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
774
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maru B, Edinboro A, Katolik A, El-Khoury R, Basran K, Wahba A, et al.
Nucleic Acids Res
. 2025 Mar;
53(5).
PMID: 40052819
Fluorescent probe-based quantitative polymerase chain reaction (qPCR) is essential for DNA/RNA quantification widely used in research and clinical diagnostics. The performance of fluorogenic probes depends heavily on their design, particularly...
2.
Kubitschek J, Takhaveev V, Mingard C, Rochlitz M, Reinert P, Keller G, et al.
Nucleic Acids Res
. 2025 Jan;
53(2).
PMID: 39831306
Temozolomide kills cancer cells by forming O6-methylguanine (O6-MeG), which leads to cell cycle arrest and apoptosis. However, O6-MeG repair by O6-methylguanine-DNA methyltransferase (MGMT) contributes to drug resistance. Characterizing genomic profiles...
3.
Osman E, Karimi K, Chen Y, Hirka S, Charles R, McKeague M
ACS Sens
. 2024 Dec;
10(1):246-253.
PMID: 39705714
We present a straightforward design approach to develop DNA-based light-up aptasensors. We performed the first systematic comparison of DNA fluorescent light-up aptamers (FLAPs), revealing key differences in affinity and specificity...
4.
Osman E, Rynes T, Wang Y, Mruk K, McKeague M
Chem Sci
. 2024 Mar;
15(13):4770-4778.
PMID: 38550682
We report a genetically encoded aptamer biosensor platform for non-invasive measurement of drug distribution in cells and animals. We combined the high specificity of aptamer molecular recognition with the easy-to-detect...
5.
Jiang Y, Mingard C, Huber S, Takhaveev V, McKeague M, Kizaki S, et al.
ACS Cent Sci
. 2024 Mar;
10(2):487.
PMID: 38435521
[This corrects the article DOI: 10.1021/acscentsci.2c01100.].
6.
Kovecses O, Mercier F, McKeague M
Leukemia
. 2024 Feb;
38(7):1441-1454.
PMID: 38424137
Differentiation therapy has proven to be a success story for patients with acute promyelocytic leukemia. However, the remaining subtypes of acute myeloid leukemia (AML) are treated with cytotoxic chemotherapies that...
7.
Rivera M, Ayon O, Diaconescu-Grabari S, Pottel J, Moitessier N, Mittermaier A, et al.
Nucleic Acids Res
. 2024 Feb;
52(6):3164-3179.
PMID: 38375901
The capacity of riboswitches to undergo conformational changes in response to binding their native ligands is closely tied to their functional roles and is an attractive target for antimicrobial drug...
8.
Maru B, Messikommer A, Huang L, Seipel K, Kovecses O, Valk P, et al.
Cell Rep Med
. 2023 Sep;
4(9):101191.
PMID: 37683650
Previous chemotherapy research has focused almost exclusively on apoptosis. Here, a standard frontline drug combination of cytarabine and idarubicin induces distinct features of caspase-independent, poly(ADP-ribose) polymerase 1 (PARP-1)-mediated programmed cell...
9.
Jiang Y, Mingard C, Huber S, Takhaveev V, McKeague M, Kizaki S, et al.
ACS Cent Sci
. 2023 Mar;
9(3):362-372.
PMID: 36968528
Chemical modifications to DNA bases, including DNA adducts arising from reactions with electrophilic chemicals, are well-known to impact cell growth, miscode during replication, and influence disease etiology. However, knowledge of...
10.
Maru B, Nadeau L, McKeague M
ACS Pharmacol Transl Sci
. 2021 Dec;
4(6):1716-1727.
PMID: 34927006
Chimeric antigen receptor (CAR) T cell therapy is a relatively new form of immunotherapy that has had success in treating patients with hematologic malignancies, leading to three recent United States...